Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04212169 | Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis | PHASE2 | COMPLETED | 148 | — | — | Dec 9, 2019 | Sep 20, 2022 | Sep 28, 2023 | 38 | United States, Australia +4 |
The EASI evaluates 4 anatomic regions for severity and extent of key disease signs and focuses on the acute and chronic signs of inflammation (ie, erythema, edema, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease. Analysis was performed using mixed effect model for repeated measures and MCP-mod dose response model.
| Arm | Type | Description |
|---|---|---|
| MEDI3506 at dose level 1 | EXPERIMENTAL | Participant will receive multiple doses of MEDI3506 at dose level 1. |
| MEDI3506 at dose level 2 | EXPERIMENTAL | Participant will receive multiple doses of MEDI3506 at dose level 2. |
| MEDI3506 at dose level 3 | EXPERIMENTAL | Participant will receive multiple doses of MEDI3506 at dose level 3. |
| Placebo | PLACEBO_COMPARATOR | Participant will receive multiple doses of Placebo |
| Name | Type | Description |
|---|---|---|
| MEDI3506 | DRUG | multiple doses |
| Placebo | DRUG | multiple doses |
Inclusion Criteria: * Age 18 to 65 years inclusive at the time of consent. * Body mass index between 19.0 and 40.0 kg/m2 inclusive. * Documented history of chronic AD, for at least 1 year prior to screening Visit 1. * Meets at minimum 1 of the criteria, as follows: * History of inadequate respon...